ABIONYX Pharma SA (609.F)

1,2640 +0,0040 (+0,32%) Ab 08:02AM CEST. Markt geöffnet.

ABIONYX Pharma SA

33 43 av. Georges Pompidou Bât. D2
Balma 31130
France
33 5 62 24 97 06
https://abionyx.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 61

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Sir Cyrille Tupin CPA	CEO, GM & Director	289,28k	N/A	1976
Prof. Christian Chavy MBA	Independent Director	28k	N/A	1950
Mr. Emmanuel De Fougeroux	Administrative & Financial Director	N/A	N/A	N/A
Ms. Constance Keyserling Peyrottes M.S.	Vice President of Clinical, Regulatory Development & Operations	N/A	N/A	1961
Dr. Robert Andrew Donald Scott M.D.	Chief Medical Officer and Head of R&D	N/A	N/A	1953
Mr. Laurent Guerci	Chief Digital & Innovation Officer	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2022 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal and ophthalmological diseases. It develops CER-001, a negatively-charged lipoprotein particle which contains human recombinant apoA-I, the natural high density lipoprotein (HDL) protein, and sphingomyelin and dipalmitoylphosphatidylglycerol natural phospholipids designed to mimicks the structural and functional biological properties of pre-beta HDL for the treatment of post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients; CER-002, a peroxisome proliferator-activated receptor delta specific agonist for the treatment of cardiovascular and metabolic diseases; and CER-209, a drug candidate for the treatment of metabolic diseases in the liver, as well as atherosclerois and non-alcoholic steato-hepatitis. The company was formerly known as Cerenis Therapeutics Holding SA and changed its name to ABIONYX Pharma SA in August 2019. ABIONYX Pharma SA was founded in 2005 and is based in Balma, France.

Corporate Governance

ABIONYX Pharma SAs ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.